Yu, Andrew; Johnson, Scott; Wang, Si-Tien; Atanasov, Pavel - In: PharmacoEconomics 27 (2009) 7, pp. 609-621
<Emphasis Type="Bold">Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease. <Emphasis Type="Bold">Methods: Maintenance regimens of adalimumab (40 mg every other...</emphasis></emphasis>